Skip to main content
Funded Studies

Accelerated Pre-clinical Development of a Novel and Specific Alpha-synuclein Tracer

Biomarkers that can communicate the underlying pathology of Parkinson’s disease (PD) in living patients would be invaluable for diagnosis and for evaluation of disease-modifying treatments. The purpose of this project is to develop tracers for use with PET imaging that can bind to misfolded alpha-synuclein, which is thought to be central to the pathology in PD.

Project Description:
To develop a PET imaging tracer for visualization of alpha-synuclein pathology on brain scans in living PD patients, researchers will refine assays (characterization tests) that will allow for screening of promising candidate tracers. They then will begin pre-clinical studies with the lead candidates that will establish the basis for clinical trials of the new tracer(s) in human.

Relevance to Diagnosis/Treatment of Parkinson’s Disease:
This project addresses the unmet need for objective measures of underlying PD pathology. A successful PET imaging tracer of alpha-synuclein would help with early detection of PD and assessment of therapies aimed at reducing the progression of PD.

Anticipated Outcome:
At the end of this study, investigators hope to have a promising candidate or set of candidates for use as PET tracers of alpha-synuclein. These tracers would then undergo additional safety assessments in pre-clinical models and could then potentially be validated in patients with Parkinson’s disease.


  • Giorgio Attardo, PhD, MSc

    Philadelphia, PA United States

  • Andrew Siderowf, MD, MSCE

    Philadelphia, PA United States

Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.